Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of GSK3277511A (NTHi-Mcat) Vaccine in Adults
NCT03201211Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of GSK3277511A in chronic obstructive pulmonary disease (COPD) and respiratory tract infection (RTI) (3 arms), sponsored by GSK. Primary endpoints: Anti-Protein D Antibody Concentrations at Month 50, Anti-Protein E Antibody Concentrations at Month 50 and 2 more. Started Jun 2017; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT03201211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201211.